Monday, January 12, 2015

TapImmune Inc announces positive phase 1 immune responses in all evaluable ovarian and breast cancer patients advances vaccine to phase II clinical trials

… for ovarian and breast cancers.Eight women with HER2-negative breast cancer, thirteen with ovarian …
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)